<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Rufinamide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06201</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB06201/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB06201/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06201.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06201.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06201.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06201.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06201.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB06201">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>RUF 331</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Xilep </td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Banzel </td><td>Eisai Inc.</td></tr><tr><td>Inovelon</td><td>Eisai Inc. </td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>106308-44-5</td></tr><tr><th>Weight</th><td>Average: 238.1935<br>Monoisotopic: 238.066617308</td></tr><tr><th>Chemical Formula</th><td>C<sub>10</sub>H<sub>8</sub>F<sub>2</sub>N<sub>4</sub>O</td></tr><tr><th>InChI Key</th><td>POGQSBRIGCQNEG-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Azoles</td></tr><tr><th>Subclass</th><td>Triazoles</td></tr><tr><th>Direct parent</th><td>Triazole Carboxylic Acids and Derivatives</td></tr><tr><th>Alternative parents</th><td>Fluorobenzenes; Aryl Fluorides; Primary Carboxylic Acid Amides; Enolates; Polyamines; Carboxylic Acids; Organofluorides</td></tr><tr><th>Substituents</th><td>fluorobenzene; aryl fluoride; aryl halide; benzene; carboxamide group; primary carboxylic acid amide; polyamine; carboxylic acid; enolate; carboxylic acid derivative; organofluoride; amine; organohalogen; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the triazole carboxylic acids and derivatives. These are heterocyclic compounds containing a triazole ring substituted by at least one carboxylic acid group (or a derivative thereof).</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Adjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome.   </td></tr><tr><th>Pharmacodynamics</th><td>At high concentrations will inhibit action of mGluR5 subtype receptors thus preventing the production of glutamate. </td></tr><tr><th>Mechanism of action</th><td>Rufinamide is a triazole derivative antiepileptic that prolongs the inactive state of voltage gated sodium channels thus stabilizing membranes, ultimately blocking the spread of partial seizure activity.</td></tr><tr><th>Absorption</th><td>The oral suspension and tablet are bioequivalent on a mg per mg basis. Rufinamide is well absorbed but the rate is slow and the extent of absorption decreases as dose is increases. Based on urinary excretion, the extent of absorption was at least 85% following oral administration of a single dose of 600 mg rufinamide tablet under fed conditions.
Bioavailability= 70%-85% (decreases with increasing doses); 
Tmax, fed and fasted states= 4-6 hours; 
Cmax, 10 mg/kg/day= 4.01 &#181;L/mL; 
Cmax, 30mg/kg/day= 8.68 &#181;L/mL;
AUC (0h-12h), 10mg/kg/day= 37.8&#177;47 &#181;g&#183;h/mL; 
AUC (0h-12h), 30mg/kg/day= 89.3&#177;59 &#181;g&#183;h/mL.  </td></tr><tr><th>Volume of distribution</th><td><p>Rufinamide was evenly distributed between erythrocytes and plasma. The apparent volume of distribution is dependent upon dose and varies with body surface area. The apparent volume of distribution was about 50 L at 3200 mg/day.<br>
Volume of distribution is similar between adults and children and is non-linear.</p></td></tr><tr><th>Protein binding</th><td>26.3% - 34.8% with 90% binding to albumin (27%).</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Rufinamide is extensively metabolized but has no active metabolites. Metabolism by carboxyesterases into inactive metabolite CGP 47292, a carboxylic acid derivative, via hydrolysis is the primary biotransformation pathway. A few minor additional metabolites were detected in urine, which appeared to be acyl-glucuronides of CGP 47292. The cytochrome P450 enzyme system or glutathiones are not involved with the metabolism of rufinamide. Rufinamide is a weak inhibitor of CYP 2E1. Rufinamide is a weak inducer of CYP 3A4 enzymes.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Rufinamide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00814">CGP 47292</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/835">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Renally (91%; 66% as CGP 47292, 2% as unchanged drug) and fecally (9%) eliminated. </td></tr><tr><th>Half life</th><td>Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours.  </td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>The most commonly observed adverse reactions (&#8805;10% and greater than placebo) were headache, dizziness, fatigue, somnolence, and nausea. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9777</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5301</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7407</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9422</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9633</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6685</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8452</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8723</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5567</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8201</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8454</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5561</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7995</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.5438</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.6126
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8415
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9945
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5067 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9484
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7869
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Eisai inc</li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Suspension</td><td>Oral</td><td>40 mg/mL</td></tr><tr><td>Tablet</td><td>Oral</td><td>100 mg, 200 mg, 400 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Decrease concentration of rufinamide thus monitor therapy </td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>Rufinamide decreases plasma concentrations of ethinyl estradiol, thus consider therapy modification </td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>Rufinamide decreases plasma concentrations of norethindrone, thus consider therapy modification </td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide.</td></tr><tr><td><a href="/drugs/DB00794">Primidone</a></td><td>Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide.</td></tr><tr><td><a href="/drugs/DB00313">Valproic Acid</a></td><td>Valproic acid may increase the therapeutic/toxic effects of Rufinamide. Consider alternate therapy or monitor for changes in Rufinamide serum concentrations, therapeutic and adverse effects if Valproic acid is initiated, discontinued or dose changed. Decreases clearance of rufinamide and is a selective inhibitor of human carboxylesterase thus increasing serum concentrations. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Food increases plasma concentrations of rufinamide and slightly decreases half-life (by 3%) </li></ul></td></tr></tbody></table>